docetaxel anhydrous has been researched along with apatorsen in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (apatorsen) | Trials (apatorsen) | Recent Studies (post-2010) (apatorsen) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 8 | 3 | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albany, C; Alter, R; Alva, A; Anderson, K; Balar, A; Bellmunt, J; Breen, T; Choueiri, TK; George, S; Grivas, P; Guancial, EA; Hahn, NM; Hoffman-Censits, J; Hoimes, C; Jacobs, C; Lalani, AA; Lauer, R; Pal, S; Picus, J; Regan, MM; Rosenberg, JE; Sonpavde, G; Stein, MN; Werner, L | 1 |
1 trial(s) available for docetaxel anhydrous and apatorsen
| Article | Year |
|---|---|
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Down-Regulation; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Middle Aged; Molecular Chaperones; Oligonucleotides; Recurrence; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2018 |